» Articles » PMID: 38676929

Metabolomics Profiling Reveals Distinct, Sex-specific Signatures in Serum and Brain Metabolomes in Mouse Models of Alzheimer's Disease

Overview
Specialties Neurology
Psychiatry
Date 2024 Apr 27
PMID 38676929
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Increasing evidence suggests that metabolic impairments contribute to early Alzheimer's disease (AD) mechanisms and subsequent dementia. Signals in metabolic pathways conserved across species can facilitate translation.

Methods: We investigated differences in serum and brain metabolites between the early-onset 5XFAD and late-onset LOAD1 (APOE4.Trem2*R47H) mouse models of AD to C57BL/6J controls at 6 months of age.

Results: We identified sex differences for several classes of metabolites, such as glycerophospholipids, sphingolipids, and amino acids. Metabolic signatures were notably different between brain and serum in both mouse models. The 5XFAD mice exhibited stronger differences in brain metabolites, whereas LOAD1 mice showed more pronounced differences in serum.

Discussion: Several of our findings were consistent with results in humans, showing glycerophospholipids reduction in serum of apolipoprotein E (apoE) ε4 carriers and replicating the serum metabolic imprint of the APOE ε4 genotype. Our work thus represents a significant step toward translating metabolic dysregulation from model organisms to human AD.

Highlights: This was a metabolomic assessment of two mouse models relevant to Alzheimer's disease. Mouse models exhibit broad sex-specific metabolic differences, similar to human study cohorts. The early-onset 5XFAD mouse model primarily alters brain metabolites while the late-onset LOAD1 model primarily changes serum metabolites. Apolipoprotein E (apoE) ε4 mice recapitulate glycerophospolipid signatures of human APOE ε4 carriers in both brain and serum.

Citing Articles

Plasma metabolomics profiles indicate sex differences of lipid metabolism in patients with Parkinson's disease.

Ling Hu , Huang Y, Wei Y, Li T, Ke W, Chen G Sci Rep. 2024; 14(1):31262.

PMID: 39732876 PMC: 11682129. DOI: 10.1038/s41598-024-82674-3.


Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?.

Capocchi J, Figueroa-Romero C, Dunham S, Faraci G, Rothman J, Whiteson K J Neurosci. 2024; 44(41).

PMID: 39384409 PMC: 11466070. DOI: 10.1523/JNEUROSCI.1295-24.2024.


Metabolomics profiling reveals distinct, sex-specific signatures in serum and brain metabolomes in mouse models of Alzheimer's disease.

Pandey R, Arnold M, Batra R, Krumsiek J, Kotredes K, Garceau D Alzheimers Dement. 2024; 20(6):3987-4001.

PMID: 38676929 PMC: 11180854. DOI: 10.1002/alz.13851.

References
1.
Menni C, Kastenmuller G, Petersen A, Bell J, Psatha M, Tsai P . Metabolomic markers reveal novel pathways of ageing and early development in human populations. Int J Epidemiol. 2013; 42(4):1111-9. PMC: 3781000. DOI: 10.1093/ije/dyt094. View

2.
Puglielli L, Ellis B, Saunders A, Kovacs D . Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem. 2003; 278(22):19777-83. DOI: 10.1074/jbc.M300466200. View

3.
Cai H, Cong W, Ji S, Rothman S, Maudsley S, Martin B . Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res. 2012; 9(1):5-17. PMC: 4097094. DOI: 10.2174/156720512799015064. View

4.
Kotredes K, Oblak A, Pandey R, Lin P, Garceau D, Williams H . Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H. Front Aging Neurosci. 2021; 13:735524. PMC: 8544520. DOI: 10.3389/fnagi.2021.735524. View

5.
Tynkkynen J, Chouraki V, van der Lee S, Hernesniemi J, Yang Q, Li S . Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts. Alzheimers Dement. 2018; 14(6):723-733. PMC: 6082422. DOI: 10.1016/j.jalz.2018.01.003. View